Elsevier

Neoplasia

Volume 7, Issue 4, April 2005, Pages 426-431
Neoplasia

Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells1

https://doi.org/10.1593/neo.04454Get rights and content
Under a Creative Commons license
open access

Abstract

Gastrin-releasing peptide receptor (GRPR) and the epidermal growth factor receptor (EGFR) are expressed in several cancers including non-small cell lung carcinoma (NSCLC). Here we demonstrate the activation of EGFR by the GRPR ligand, gastrin-releasing peptide (GRP), in NSCLC cells. GRP induced rapid activation of p44/42 MAPK in lung cancer cells through EGFR. GRP-mediated activation of MAPK in NSCLC cells was abrogated by pretreatment with the anti-EGFR-neutralizing antibody, C225. Pretreatment of NSCLC cells with neutralizing antibodies to the EGFR ligands, TGF-α or HB-EGF, also decreased GRP-mediated MAPK activation. On matrix metalloproteinase (MMP) inhibition, GRP failed to activate MAPK in NSCLC cells. EGF and GRP both stimulated NSCLC proliferation, and inhibition of either EGFR or GRPR resulted in cell death. Combining a GRPR antagonist with the EGFR tyrosine kinase inhibitor, gefitinib, resulted in additive cytotoxic effects. Additive effects were seen at gefitinib concentrations from 1 to 18μM, encompassing the ID50 values of both gefitinib-sensitive and gefitinib-resistant NSCLC cell lines. Because a major effect of GRPR appears to be promoting the release of EGFR ligand, this study suggests that a greater inhibition of cell proliferation may occur by abrogating EGFR ligand release in consort with inhibition of EGFR.

Keywords

EGFR
GRPR
MAPK
signal transduction
non-small cell
lung carcinoma

Cited by (0)

1

This work was supported by a grant (U01 CA84968) from the Early Detection Research Network (J.R.G. and J.M.S.), a grant (P50 CA90440) from the Specialized Program of Research Excellence (J.M.S.), and a National Institutes of Health grant (1 R01 CA 098372-01). S.M.T. and V.Y.W.L. were supported by Career Development Awards from the University of Pittsburgh Lung Cancer SPORE.